Skip to content
Screener

Regeneron Pharmaceuticals REGN Q4 2025 Annual earnings

Reported January 30, 2026 · Before market open

Revenue$3.9BBeat by $73.6M
EPS$11.44Beat by $0.70
Revenue estimate$3.8B
EPS estimate$10.74

Next report

Oct 30, 2026 (In 3 weeks)
Revenue estimate$4.5B
EPS estimate$15.99

Financials

Q4 2025

Income statement

See full
Revenue$3.9B+2.5%
Operating income$879.9M-11.1%
Net income$844.6M-8.0%
EPS (diluted)$7.87-3.0%

Balance sheet

See full
Cash & equivalents$3.1B+25.5%
Total debt$3.0B+1.2%
Total equity$31.3B+6.5%
Total assets$40.6B+7.4%

Cash flow

See full
Operating cash flow$1.2B-7.3%
CapEx$248.7M+24.6%
Free cash flow$922.0M-13.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$81.12B+3.6%
Enterprise value$80.97B+2.9%
P/E18×+0.3×
P/S5.7×+0.1×

Profitability

See full
Operating margin24.9%-3.2pp
Net margin31.4%+0.3pp
FCF margin28.4%+2.6pp

Returns & leverage

See full
Return on equity14.9%-1.1pp
Debt / equity0.1×0.0×
Current ratio4.1×-0.6×

FAQ

When did Regeneron Pharmaceuticals report Q4 2025 earnings?
Regeneron Pharmaceuticals (REGN) reported Q4 2025 earnings on January 30, 2026 before market open.
What were Regeneron Pharmaceuticals's Q4 2025 revenue and EPS?
Regeneron Pharmaceuticals reported revenue of $3.9B and eps of $11.44 for Q4 2025.
Did Regeneron Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $3.8B by $73.6M. EPS beat the consensus estimate of $10.74 by $0.70.
How did Regeneron Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.5% from $3.8B a year earlier and eps declined 5.2% from $12.07.
Where can I find Regeneron Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0000872589-26-000004) and the 10-K periodic report (0000872589-26-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.